Investment Summary |
|
|---|---|
| Date | 2025-10-23 |
| Target | Adler Ortho |
| Sector | Medical Products |
| Investor(s) | Andera Partners |
| Deal Type | Stake Purchase |
SEARCH BY
| Category | Private Equity Firm |
|---|---|
| Founded | 2001 |
| PE ASSETS | 3.7B EUR |
| Size | Large |
| Type | Sector Agnostic |
Andera Partners is a private investment firm focused on several strategies. The Firm invests in life science opportunities through its BioDiscovery group. The Firm invests in Western European small to mid-sized companies (€30 to €300 million of revenue) through its Winch Capital group. Andera invests in small to mid-sized French companies (€10 to €100 million of revenue) through its Cabestan Capital team. Andera invests in €5 to €45 million of mezzanine capital to support small to mid-sized French companies. Andera Partners was established in 2001 and is headquartered in Paris.
| DEAL STATS | # |
|---|---|
| Overall | 123 of 123 |
| Sector: Medical Products M&A | 8 of 8 |
| Type: Stake Purchase M&A Deals | 17 of 17 |
| Country: Italy M&A | 5 of 5 |
| Year: 2025 M&A | 4 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-10-22 |
Imcheck Therapeutics
Marseilles, France ImCheck Therapeutics is a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel superfamily of immunomodulators. Its clinical-stage program, ICT01, has been advancing to late-stage trials, demonstrating a unique mechanism of action that modulates both innate and adaptive immunity. These “first-in-class” activating antibodies may deliver superior clinical outcomes compared to first-generation immunotherapy approaches, in particular in rational combinations with immune checkpoint inhibitors and immunomodulatory anti-cancer drugs. Imcheck Therapeutics was founded in 2015 and is based in Marseilles, France. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-11-05 |
Evommune
Palo Alto, California, United States Evommune is a biopharmaceutical company developing innovative therapies in the area of chronic inflammation, particularly in dermatological conditions. Evommune was founded in 2020 and is based in Palo Alto, California. |
Sell | - |
